Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Our objective was to compare the predictive value of the well-established tumour marker CA125 with the newer tumour markers tetranectin (TN), OVX1 and CASA in distinguishing benign and malignant pelvic masses in women. Participants included 185 women, 19 years or older, with a pelvic mass planned for surgical exploration. Significantly different CA125 levels were found between benign tumours and localised ovarian cancer (OC), advanced OC and other non-OCs. Significantly different TN levels were found between benign tumours and advanced OC (stage III/IV), between benign tumours and other cancers and between all OCs and other cancers. For CASA, significant differences were found between benign tumours and all OCs as well as advanced OC. No significant differences could be demonstrated for OVX1. Significant correlations for the 44 OC patients were found between CA125, TN and CASA. No significant correlations were found for OVX1, possibly because of the method used for collection and handling of serum samples. None of the new markers had any additional predictive value compared to CA125. TN and CASA levels correlated with FIGO stage and could be used to discriminate between benign and advanced OC. However, in comparison to the performance of CA125, the additional discriminative value of TN and CASA was minor.
Hogdall
E V
EV
Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. estrid@cancer.dk
Høgdall
C K
CK
Tingulstad
S
S
Hagen
B
B
Nustad
K
K
Xu
F J
FJ
Bast
R C
RC
Jacobs
I J
IJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D001798:Blood Proteins / Q000378:metabolism*; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006023:Glycoproteins; D006801:Humans; D037181:Lectins, C-Type; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology; D010386:Pelvic Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D011237:Predictive Value of Tests; D011506:Proteins; D012372:ROC Curve; D012680:Sensitivity and Specificity
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D001798:Blood Proteins; D018394:CA-125 Antigen; C121307:CASA antigen; D006023:Glycoproteins; D037181:Lectins, C-Type; C086414:OVX1 antigen; D011506:Proteins; C048648:tetranectin